FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1667-1675 December 6, 2001 Number 23 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.

Methods A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.

Results Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure: 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting–enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.

Conclusions Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.

Source Information

From the Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (J.N.C.); and the Mario Negri Institute, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, Milan, Italy (G.T.).

Address reprint requests to Dr. Cohn at the Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St., SE, Minneapolis, MN 55455.

Full Text of this Article

This article has been cited by other articles:

• Teo, K. K. (2009). Clinical evidence from ONTARGET: proven cardio- and vascular protection. Eur Heart J Suppl 11: F9-F15 [Abstract] [Full Text]  
• Bohm, M., Mahfoud, F., Werner, C., Teo, K., Baumhakel, M. (2009). Cardiovascular protection: a breakthrough for high-risk patients. Eur Heart J Suppl 11: F19-F26 [Abstract] [Full Text]  
• Frimodt-Moller, M., Hoj Nielsen, A., Strandgaard, S., Kamper, A.-L. (2009). Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant 0: gfp547v1-gfp547 [Abstract] [Full Text]  
• Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., Sun, Y., Wasserman, S. M., van Veldhuisen, D. J. (2009). The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 11: 1071-1077 [Abstract] [Full Text]  
• Zucker, I. H., Schultz, H. D., Patel, K. P., Wang, W., Gao, L. (2009). Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am. J. Physiol. Heart Circ. Physiol. 297: H1557-H1566 [Abstract] [Full Text]  
• van den Borne, S. W.M., van de Schans, V. A.M., Strzelecka, A. E., Vervoort-Peters, H. T.M., Lijnen, P. M., Cleutjens, J. P.M., Smits, J. F.M., Daemen, M. J.A.P., Janssen, B. J.A., Blankesteijn, W. M. (2009). Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc Res 84: 273-282 [Abstract] [Full Text]  
• Zannad, F., Agrinier, N., Alla, F. (2009). Heart failure burden and therapy. Europace 11: v1-v9 [Abstract] [Full Text]  
• Anand, I. S., Bishu, K., Rector, T. S., Ishani, A., Kuskowski, M. A., Cohn, J. N. (2009). Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure. Circulation 120: 1577-1584 [Abstract] [Full Text]  
• Baker, W. L., Coleman, C. I., Kluger, J., Reinhart, K. M., Talati, R., Quercia, R., Phung, O. J., White, C. M. (2009). Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease. ANN INTERN MED 0: 0000605-200912150-00162v1-E-162 [Abstract] [Full Text]  
• Sawada, T., Yamada, H., Dahlof, B., Matsubara, H., for the KYOTO HEART Study Group, (2009). Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 30: 2461-2469 [Abstract] [Full Text]  
• Levy, W. C., Lee, K. L., Hellkamp, A. S., Poole, J. E., Mozaffarian, D., Linker, D. T., Maggioni, A. P., Anand, I., Poole-Wilson, P. A., Fishbein, D. P., Johnson, G., Anderson, J., Mark, D. B., Bardy, G. H. (2009). Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. Circulation 120: 835-842 [Abstract] [Full Text]  
• Hsich, E. M., Pina, I. L. (2009). Heart failure in women: a need for prospective data.. J Am Coll Cardiol 54: 491-498 [Abstract] [Full Text]  
• Campian, M. E., Verberne, H. J., Hardziyenka, M., de Bruin, K., Selwaness, M., van den Hoff, M. J.B., Ruijter, J. M., van Eck-Smit, B. L.F., de Bakker, J. M.T., Tan, H. L. (2009). Serial Noninvasive Assessment of Apoptosis During Right Ventricular Disease Progression in Rats. JNM 50: 1371-1377 [Abstract] [Full Text]  
• Pitt, B. (2009). RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. Heart 95: 1205-1208 [Full Text]  
• McMurray, J. J.V., Granger, C. B., Ostergren, J., Yusuf, S., Pfeffer, M. A., Swedberg, K. (2009). Dual Renin-Angiotensin system blockade in heart failure.. J Am Coll Cardiol 54: 278-278 [Full Text]  
• Jackevicius, C. A., Cox, J. L., Carreon, D., Tu, J. V., Rinfret, S., So, D., Johansen, H., Kalavrouziotis, D., Demers, V., Humphries, K., Pilote, L., for the Canadian Cardiovascular Outcomes Research, (2009). Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 181: E19-E28 [Abstract] [Full Text]  
• Baliga, V., Sapsford, R. (2009). Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management. Diabetes and Vascular Disease Research 6: 164-171 [Abstract]  
• Bansal, S., Lindenfeld, J., Schrier, R. W. (2009). Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?. Circ Heart Fail 2: 370-376 [Abstract] [Full Text]  
• Gonzalez, G. E., Seropian, I. M., Krieger, M. L., Palleiro, J., Lopez Verrilli, M. A., Gironacci, M. M., Cavallero, S., Wilensky, L., Tomasi, V. H., Gelpi, R. J., Morales, C. (2009). Effect of early versus late AT1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am. J. Physiol. Heart Circ. Physiol. 297: H375-H386 [Abstract] [Full Text]  
• Elijovich, F., Laffer, C. (2009). A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 3: 231-240 [Abstract]  
• Dixon, J. A., Spinale, F. G. (2009). Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice. Circ Heart Fail 2: 262-271 [Abstract] [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: 1343-1382 [Full Text]  
• 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, , Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• O'Connor, C. M., Whellan, D. J., Lee, K. L., Keteyian, S. J., Cooper, L. S., Ellis, S. J., Leifer, E. S., Kraus, W. E., Kitzman, D. W., Blumenthal, J. A., Rendall, D. S., Miller, N. H., Fleg, J. L., Schulman, K. A., McKelvie, R. S., Zannad, F., Pina, I. L., for the HF-ACTION Investigators, (2009). Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure: HF-ACTION Randomized Controlled Trial. JAMA 301: 1439-1450 [Abstract] [Full Text]  
• White, M., Rouleau, J.-L., Afzal, R., Floras, J., Yusuf, S., McKelvie, R. S. (2009). Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. Ther Adv Cardiovasc Dis 3: 113-121 [Abstract]  
• Nuzum, D. S., Merz, T. (2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice 22: 135-148 [Abstract]  
• Cleland, J. G.F., Cullington, D. (2009). Digoxin: Quo Vadis?. Circ Heart Fail 2: 81-85 [Full Text]  
• Baumhakel, M., Muller, U., Bohm, M. (2009). Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 11: 299-303 [Abstract] [Full Text]  
• Dunn, S. P., Bleske, B., Dorsch, M., Macaulay, T., Van Tassell, B., Vardeny, O. (2009). Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies. Nutr Clin Pract 24: 60-75 [Abstract] [Full Text]  
• van den Borne, S. W.M., Isobe, S., Zandbergen, H. R., Li, P., Petrov, A., Wong, N. D., Fujimoto, S., Fujimoto, A., Lovhaug, D., Smits, J. F.M., Daemen, M. J.A.P., Blankesteijn, W. M., Reutelingsperger, C., Zannad, F., Narula, N., Vannan, M. A., Pitt, B., Hofstra, L., Narula, J. (2009). Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.. J Am Coll Cardiol Img 2: 187-198 [Abstract] [Full Text]  
• Fried, L. F., Duckworth, W., Zhang, J. H., O'Connor, T., Brophy, M., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S., Warren, S. R., Peduzzi, P., for VA NEPHRON-D Investigators, (2009). Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). CJASN 4: 361-368 [Abstract] [Full Text]  
• Ripley, T. L., Nutescu, E. (2009). Anticoagulation in patients with heart failure and normal sinus rhythm. Am J Health Syst Pharm 66: 134-141 [Abstract] [Full Text]  
• Hollenberg, S. M. (2009). Heart Failure and Cardiac Pulmonary Edema. ACCP Crit Care Med Brd Rev 20: 117-128 [Full Text]  
• Orso, F., Baldasseroni, S., Fabbri, G., Gonzini, L., Lucci, D., D'Ambrosi, C., Gobbi, M., Lecchi, G., Randazzo, S., Masotti, G., Tavazzi, L., Maggioni, A. P., on behalf of Italian Survey on Acute Heart Failure, (2009). Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail 11: 77-84 [Abstract] [Full Text]  
• Zannad, F., Bousquet, P., Monassier, L. (2009). CHAPTER 11 Clinical Pharmacology of Cardiovascular Drugs. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Kjeldsen, S. E., Aksnes, T. A., Fagard, R. H., Mancia, G. (2009). CHAPTER 13 Hypertension. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• McMurray, J., Petrie, M., Swedberg, K., Komajda, M., Anker, S., Gardner, R. (2009). CHAPTER 23 Heart Failure. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• van den Borne, S. W.M., Isobe, S., Verjans, J. W., Petrov, A., Lovhaug, D., Li, P., Zandbergen, H. R., Ni, Y., Frederik, P., Zhou, J., Arbo, B., Rogstad, A., Cuthbertson, A., Chettibi, S., Reutelingsperger, C., Blankesteijn, W. M., Smits, J. F.M., Daemen, M. J.A.P., Zannad, F., Vannan, M. A., Narula, N., Pitt, B., Hofstra, L., Narula, J. (2008). Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. J Am Coll Cardiol 52: 2017-2028 [Abstract] [Full Text]  
• Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., Ptaszynska, A., the I-PRESERVE Investigators, (2008). Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. NEJM 359: 2456-2467 [Abstract] [Full Text]  
• Henz, S., Maeder, M. T., Huber, S., Schmid, M., Loher, M., Fehr, T. (2008). Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrol Dial Transplant 23: 3939-3945 [Abstract] [Full Text]  
• Nieminen, M. S., Cleland, J. G.F., Eha, J., Belenkov, Y., Kivikko, M., Poder, P., Sarapohja, T. (2008). Oral levosimendan in patients with severe chronic heart failure--The PERSIST study. Eur J Heart Fail 10: 1246-1254 [Abstract] [Full Text]  
• Ellmers, L. J., Scott, N. J. A., Medicherla, S., Pilbrow, A. P., Bridgman, P. G., Yandle, T. G., Richards, A. M., Protter, A. A., Cameron, V. A. (2008). Transforming Growth Factor-{beta} Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction. Endocrinology 149: 5828-5834 [Abstract] [Full Text]  
• Authors/Task Force Members, , Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Tendera, M., Auricchio, A., Bax, J., Bohm, M., Corra, U., della Bella, P., Elliott, P. M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.-L., Verheugt, F. W. A., Zamorano, J. L., Zannad, F. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442 [Full Text]  
• Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989 [Full Text]  
• Franks, A. M, O'Brien, C. E, Stowe, C. D, Wells, T. G, Gardner, S. F (2008). Candesartan Cilexetil Effectively Reduces Blood Pressure in Hypertensive Children. The Annals of Pharmacotherapy 42: 1388-1395 [Abstract] [Full Text]  
• Masson, S., Latini, R., Anand, I. S., Barlera, S., Angelici, L., Vago, T., Tognoni, G., Cohn, J. N., for the Val-HeFT Investigators, (2008). Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52: 997-1003 [Abstract] [Full Text]  
• Krum, H. (2008). Role of renin in heart failure and therapeutic potential of direct renin inhibition. Journal of Renin-Angiotensin-Aldosterone System 9: 177-180  
• Crespo, M. J., Cruz, N., Altieri, P. I., Escobales, N. (2008). Enalapril and Losartan Are More Effective Than Carvedilol in Preventing Dilated Cardiomyopathy in the Syrian Cardiomyopathic Hamster. J CARDIOVASC PHARMACOL THER 13: 199-206 [Abstract]  
• Hauptman, P. J. (2008). All clinical trials are not created equal: The dilemma of HEAAL. Eur J Heart Fail 10: 817-818 [Full Text]  
• Konstam, M. A., Poole-Wilson, P. A., Dickstein, K., Drexler, H., Justice, S. J., Komajda, M., Malbecq, W., Martinez, F. A., Neaton, J. D., Riegger, G. A.J., Guptha, S. (2008). Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Eur J Heart Fail 10: 899-906 [Abstract] [Full Text]  
• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Ther Adv Cardiovasc Dis 2: 233-248 [Abstract]  
• Ootaki, C., Yamashita, M., Ootaki, Y., Kamohara, K., Weber, S., Klatte, R. S., Smith, W. A., Massiello, A. L., Emancipator, S. N., Golding, L. A.R., Fukamachi, K. (2008). Reduced Pulsatility Induces Periarteritis in Kidney: Role of the Local Renin-Angiotensin System. J. Thorac. Cardiovasc. Surg. 136: 150-158 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• de Denus, S., Zakrzewski-Jakubiak, M., Dube, M.-P., Belanger, F., Lepage, S., Leblanc, M.-H., Gossard, D., Ducharme, A., Racine, N., Whittom, L., Lavoie, J., Touyz, R. M, Turgeon, J., White, M. (2008). Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan. The Annals of Pharmacotherapy 42: 925-932 [Abstract] [Full Text]  
• Werner, C. M., Bohm, M. (2008). Review: The therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis 2: 167-177 [Abstract]  
• Kasama, S., Toyama, T., Sumino, H., Nakazawa, M., Matsumoto, N., Sato, Y., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M. (2008). Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. JNM 49: 907-914 [Abstract] [Full Text]  
• MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., McMurray, J. J.V. (2008). Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29: 1224-1240 [Abstract] [Full Text]  
• McMurray, J. J.V., Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Keefe, D. L., Ford, J., Verma, A., Lewsey, J., for the Aliskiren Observation of Heart Failure Tre, (2008). Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circ Heart Fail 1: 17-24 [Abstract] [Full Text]  
• Anand, I. S., Rector, T. S., Kuskowski, M., Thomas, S., Holwerda, N.J., Cohn, J. N. (2008). Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 1: 34-42 [Abstract] [Full Text]  
• Verjans, J. W.H., Lovhaug, D., Narula, N., Petrov, A. D., Indrevoll, B., Bjurgert, E., Krasieva, T. B., Petersen, L. B., Kindberg, G. M., Solbakken, M., Cuthbertson, A., Vannan, M. A., Reutelingsperger, C. P.M., Tromberg, B. J., Hofstra, L., Narula, J. (2008). Noninvasive imaging of angiotensin receptors after myocardial infarction.. J Am Coll Cardiol Img 1: 354-362 [Abstract] [Full Text]  
• McMurray, J. J.V. (2008). ACE Inhibitors in Cardiovascular Disease -- Unbeatable?. NEJM 358: 1615-1616 [Full Text]  
• The ONTARGET Investigators, (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 358: 1547-1559 [Abstract] [Full Text]  
• Coffman, T. M., Crowley, S. D. (2008). Kidney in Hypertension: Guyton Redux. Hypertension 51: 811-816 [Full Text]  
• Bourge, R. C., Abraham, W. T., Adamson, P. B., Aaron, M. F., Aranda, J. M. Jr, Magalski, A., Zile, M. R., Smith, A. L., Smart, F. W., O'Shaughnessy, M. A., Jessup, M. L., Sparks, B., Naftel, D. L., Stevenson, L. W., on behalf of the COMPASS-HF Study Group, (2008). Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.. J Am Coll Cardiol 51: 1073-1079 [Abstract] [Full Text]  
• Agirbasli, M., Cincin, A., Baykan, O. A (2008). Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors. Journal of Renin-Angiotensin-Aldosterone System 9: 22-26 [Abstract]  
• Gradman, A. H., Kad, R. (2008). Renin inhibition in hypertension.. J Am Coll Cardiol 51: 519-528 [Abstract] [Full Text]  
• Choudhary, R., Palm-Leis, A., Scott, R. C. III, Guleria, R. S., Rachut, E., Baker, K. M., Pan, J. (2008). All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 294: H633-H644 [Abstract] [Full Text]  
• Goldstein, N. E., Fischberg, D. (2008). Update in Palliative Medicine. ANN INTERN MED 148: 135-140 [Full Text]  
• Yagi, S., Aihara, K.-i., Ikeda, Y., Sumitomo, Y., Yoshida, S., Ise, T., Iwase, T., Ishikawa, K., Azuma, H., Akaike, M., Matsumoto, T. (2008). Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency. Circ. Res. 102: 68-76 [Abstract] [Full Text]  
• Triller, D. M., Hamilton, R. A. (2007). Effect of pharmaceutical care services on outcomes for home care patients with heart failure. Am J Health Syst Pharm 64: 2244-2249 [Abstract] [Full Text]  
• Parikh, N. I., Gona, P., Larson, M. G., Wang, T. J., Newton-Cheh, C., Levy, D., Benjamin, E. J., Kannel, W. B., Vasan, R. S. (2007). Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28: 2644-2652 [Abstract] [Full Text]  
• Seed, A., Gardner, R., McMurray, J., Hillier, C., Murdoch, D., MacFadyen, R., Bobillier, A., Mann, J., McDonagh, T. (2007). Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 9: 1120-1127 [Abstract] [Full Text]  
• Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., Krumholz, H. M. (2007). Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. Arch Intern Med 167: 1930-1936 [Abstract] [Full Text]  
• Latini, R., Masson, S., Anand, I. S., Missov, E., Carlson, M., Vago, T., Angelici, L., Barlera, S., Parrinello, G., Maggioni, A. P., Tognoni, G., Cohn, J. N., for the Val-HeFT Investigators, (2007). Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. Circulation 116: 1242-1249 [Abstract] [Full Text]  
• Duckelmann, C., Mittermayer, F., Haider, D. G., Altenberger, J., Eichinger, J., Wolzt, M. (2007). Asymmetric Dimethylarginine Enhances Cardiovascular Risk Prediction in Patients With Chronic Heart Failure. Arterioscler. Thromb. Vasc. Bio. 27: 2037-2042 [Abstract] [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 50: e28-e55 [Full Text]  
• Mozaffarian, D., Anker, S. D., Anand, I., Linker, D. T., Sullivan, M. D., Cleland, J. G.F., Carson, P. E., Maggioni, A. P., Mann, D. L., Pitt, B., Poole-Wilson, P. A., Levy, W. C. (2007). Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model. Circulation 116: 392-398 [Abstract] [Full Text]  
• Marciante, K. D., Bis, J. C., Rieder, M. J., Reiner, A. P., Lumley, T., Monks, S. A., Kooperberg, C., Carlson, C., Heckbert, S. R., Psaty, B. M. (2007). Renin-Angiotensin System Haplotypes and the Risk of Myocardial Infarction and Stroke in Pharmacologically Treated Hypertensive Patients. Am J Epidemiol 166: 19-27 [Abstract] [Full Text]  
• Hennekens, C. H., Pfeffer, M. A., Swedberg, K. (2007). The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. J CARDIOVASC PHARMACOL THER 12: 124-126 [Abstract]  
• Keyhan, G., Chen, S.-F., Pilote, L. (2007). Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail 9: 594-601 [Abstract] [Full Text]